Form 8-K - Current report:
SEC Accession No. 0001104659-25-081924
Filing Date
2025-08-22
Accepted
2025-08-22 16:39:35
Documents
15
Period of Report
2025-08-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2524070d1_8k.htm   iXBRL 8-K 29813
2 EXHIBIT 1.1 tm2524070d1_ex1-1.htm EX-1.1 15192
3 EXHIBIT 5.1 tm2524070d1_ex5-1.htm EX-5.1 10920
7 GRAPHIC tm2524070d1_ex5-1img001.jpg GRAPHIC 3950
  Complete submission text file 0001104659-25-081924.txt   234635

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA plx-20250822.xsd EX-101.SCH 3011
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE plx-20250822_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE plx-20250822_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2524070d1_8k_htm.xml XML 3682
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 251246804
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)